A 62-year-old with new HFrEF (LVEF 30%) on lisinopril and metoprolol succinate remains NYHA II with BP 118/70 and eGFR 62 mL/min/1.73 m². Which evidence-based addition is a core component of foundational therapy to reduce mortality and HF hospitalization regardless of diabetes status?